A giant in molecular diagnostics, Qiagen is now working in a new diagnostic test that could help guide the treatment of breast cancer.
Now, Qiagen has partnered with Therawis Diagnostics, a Munich-based company focused in oncology and predictive tests. Its most advanced programme is to predict how effective certain chemotherapeutic drugs will be against breast cancer.
The main focus is anthracycline, a drug currently used to treat patients with high-risk breast cancer. This therapy has serious side effects (such as congestive heart failure or leukemia), and has a relatively low response rate in patients – 50% or less.
A particular type of cancer that has a poor prognosis is triple-negative breast cancer (TNBC). Only about 35% of TNBC patients respond to the chemotherapy,